Key facts
- It has raised $148.7M; the latest was Later Stage VC in Dec 2024.
- Notable investors include CICC Capital, Legend Capital, Beijing State-owned Capital Operation and Management, QF Capital, China Reform Holdings Corporation — 20 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 20 names
- ·Watchlist + deal alerts for SAFE Pharmaceutical
- ·The full record, as it builds
Funding rounds
No funding rounds for SAFE Pharmaceutical are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About SAFE Pharmaceutical
Provider of contract research services intended to serve pharmaceutical research and development enterprise. The company is a Contract Research Organization (CRO) that provides one-stop medicine services including R&D consulting, toxicology evaluations and clinical trial design, enabling pharmaceutical developers to research and develop products efficiently.
- Sector
- Healthcare
- HQ
- Beijing, China
- Founded
- 2016
- Website
- safeglp.com/
- Ownership
- Privately Held (backing)
SAFE Pharmaceutical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in SAFE Pharmaceutical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on SAFE Pharmaceutical in its N-PORT filings yet. We sweep new filings monthly.